Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
- PMID: 8285590
- DOI: 10.1002/ana.410350107
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
Abstract
Brain tissue from normal individuals with incidental Lewy bodies and cell loss in pigmented substantia nigra neurons (asymptomatic Parkinson's disease) and age-matched control subjects without nigral Lewy bodies was examined biochemically. There was no difference in dopamine levels or dopamine turnover in the caudate and putamen of individuals with incidental Lewy body disease compared to control subjects. There were no differences in levels of iron, copper, manganese, or zinc in the substantia nigra or other brain regions from the individuals with incidental Lewy body disease compared to those from control subjects. Similarly, ferritin levels in the substantia nigra and other brain areas were unaltered. There was no difference in the activity of succinate cytochrome c reductase (complexes II and III) or cytochrome oxidase (complex IV) between incidental Lewy body subjects and control subjects. Rotenone-sensitive NADH coenzyme Q1 reductase activity (complex I) was reduced to levels intermediate between those in control subjects and those in patients with overt Parkinson's disease, but this change did not reach statistical significance. The levels of reduced glutathione in substantia nigra were reduced by 35% in patients with incidental Lewy body disease compared to control subjects. Reduced glutathione levels in other brain regions were unaffected and there were no changes in oxidized glutathione levels in any brain region. Altered iron metabolism is not detectable in the early stages of nigral dopamine cell degeneration. There may be some impairment of mitochondrial complex I activity in the substantia nigra in Parkinson's disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.Ann Neurol. 1994 Sep;36(3):348-55. doi: 10.1002/ana.410360305. Ann Neurol. 1994. PMID: 8080242
-
Presymptomatic detection of Parkinson's disease.J Neural Transm Suppl. 1993;40:23-36. J Neural Transm Suppl. 1993. PMID: 8294898 Review.
-
What process causes nigral cell death in Parkinson's disease?Neurol Clin. 1992 May;10(2):387-403. Neurol Clin. 1992. PMID: 1584181 Review.
-
Complex I, iron, and ferritin in Parkinson's disease substantia nigra.Ann Neurol. 1994 Dec;36(6):876-81. doi: 10.1002/ana.410360612. Ann Neurol. 1994. PMID: 7998774
Cited by
-
Parkin and mitophagy in cancer.Oncogene. 2017 Mar;36(10):1315-1327. doi: 10.1038/onc.2016.302. Epub 2016 Sep 5. Oncogene. 2017. PMID: 27593930 Review.
-
Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.J Mol Neurosci. 2016 Nov;60(3):279-288. doi: 10.1007/s12031-016-0809-5. Epub 2016 Aug 8. J Mol Neurosci. 2016. PMID: 27498879 Review.
-
Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases.Neurol Sci. 2021 Apr;42(4):1473-1482. doi: 10.1007/s10072-020-04686-x. Epub 2020 Aug 20. Neurol Sci. 2021. PMID: 32816165
-
Early Parkinson's disease: what is the best approach to treatment.Drugs Aging. 2000 Sep;17(3):165-81. doi: 10.2165/00002512-200017030-00002. Drugs Aging. 2000. PMID: 11043817 Review.
-
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059. Sci Transl Med. 2010. PMID: 20926834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical